000283095 001__ 283095
000283095 005__ 20251230135418.0
000283095 0247_ $$2doi$$a10.1002/alz70862_110180
000283095 0247_ $$2pmid$$apmid:41433469
000283095 0247_ $$2pmc$$apmc:PMC12725594
000283095 0247_ $$2ISSN$$a1552-5260
000283095 0247_ $$2ISSN$$a1552-5279
000283095 037__ $$aDZNE-2025-01502
000283095 041__ $$aEnglish
000283095 082__ $$a610
000283095 1001_ $$aBiel, Davina$$b0
000283095 1112_ $$aAlzheimer’s Association International Conference$$cToronto$$d2025-07-27 - 2025-07-31$$gAAIC 25$$wCanada
000283095 245__ $$aPlasma p‐tau217 as a suitable biomarker for monitoring cognitive changes in Alzheimer’s disease
000283095 260__ $$c2025
000283095 3367_ $$0PUB:(DE-HGF)1$$2PUB:(DE-HGF)$$aAbstract$$babstract$$mabstract$$s1767099076_6285
000283095 3367_ $$033$$2EndNote$$aConference Paper
000283095 3367_ $$2BibTeX$$aINPROCEEDINGS
000283095 3367_ $$2DRIVER$$aconferenceObject
000283095 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$mjournal
000283095 3367_ $$2DataCite$$aOutput Types/Conference Abstract
000283095 3367_ $$2ORCID$$aOTHER
000283095 520__ $$aWith the approval of anti-amyloid therapies in Alzheimer's disease (AD), surrogate biomarkers are urgently needed to monitor treatment effects that translate into clinical benefits. Candidate biomarkers, including amyloid-PET, tau-PET, plasma phosphorylated tau (p-tau), and MRI-assessed atrophy, capture core pathophysiological changes in AD. While cross-sectional biomarker assessments are critical for diagnosis and staging, biomarker change rates may better reflect disease dynamics, making them more suitable for monitoring treatment efficacy. Therefore, we determined which biomarker most effectively tracks cognitive changes in AD, identifying those best suited for efficient monitoring of disease-modifying treatments.We leveraged ADNI (N = 108) and A4 (N = 151) participants with longitudinal AD biomarker data (global amyloid-PET, temporal meta tau-PET, plasma p-tau217, MRI-assessed cortical thickness in the AD signature region) together with cognitive assessments (ADNI: MMSE, ADAS13, CDR-SB; A4: MMSE, PACC). Linear mixed models were used to calculate change rates for biomarkers and cognition. To test whether biomarker changes track cognitive decline, linear models were applied, to test biomarker change rates as a predictor of cognitive change rates. Standardized beta values from bootstrapped linear models were extracted to compare the strengths of correlations between biomarkers and cognitive decline. For non-parametric comparisons, 95% confidence intervals (CIs) of standardized beta values were compared. Models were controlled for age, sex, education, and baseline cognition, with ADNI models additionally adjusted for clinical status.In both cohorts, changes in temporal tau-PET, plasma p-tau217, and MRI-assessed cortical thickness were associated with cognitive decline (ADNI: Figure 1; A4: Figure 2). Amyloid-PET changes showed no significant association with cognitive changes (ADNI: Figure 1A+F+K; A4: Figure 2A+F). Bootstrapping confirmed that tau-PET, plasma p-tau217, and cortical thickness track cognitive decline, but not amyloid-PET (ADNI: Figure 1E+J+O; A4: Figure 2E+J). Overlapping CIs for tau-PET and plasma p-tau217 indicated comparable predictive accuracy.Our findings demonstrate that tau-PET and plasma p-tau217 are robust biomarkers for monitoring cognitive changes, with plasma p-tau217 offering a cost-effective, scalable alternative for clinical use. Changes in amyloid-PET do not reliably reflect cognitive decline, limiting its utility as a treatment monitoring tool. Although cortical thickness correlates with cognitive changes, its application is limited by pseudoatrophy and volume loss induced by anti-amyloid antibody treatments.
000283095 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000283095 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000283095 650_7 $$2NLM Chemicals$$atau Proteins
000283095 650_7 $$2NLM Chemicals$$aBiomarkers
000283095 650_7 $$2NLM Chemicals$$aAmyloid beta-Peptides
000283095 650_2 $$2MeSH$$aHumans
000283095 650_2 $$2MeSH$$aAlzheimer Disease: diagnostic imaging
000283095 650_2 $$2MeSH$$aAlzheimer Disease: pathology
000283095 650_2 $$2MeSH$$aMale
000283095 650_2 $$2MeSH$$aFemale
000283095 650_2 $$2MeSH$$atau Proteins: blood
000283095 650_2 $$2MeSH$$aBiomarkers: blood
000283095 650_2 $$2MeSH$$aAged
000283095 650_2 $$2MeSH$$aMagnetic Resonance Imaging
000283095 650_2 $$2MeSH$$aPositron-Emission Tomography
000283095 650_2 $$2MeSH$$aLongitudinal Studies
000283095 650_2 $$2MeSH$$aAged, 80 and over
000283095 650_2 $$2MeSH$$aBrain: diagnostic imaging
000283095 650_2 $$2MeSH$$aBrain: pathology
000283095 650_2 $$2MeSH$$aAmyloid beta-Peptides
000283095 7001_ $$aSteward, Anna$$b1
000283095 7001_ $$aDewenter, Anna$$b2
000283095 7001_ $$aDehsarvi, Amir$$b3
000283095 7001_ $$aZhu, Zeyu$$b4
000283095 7001_ $$aRoemer-Cassiano, Sebastian$$b5
000283095 7001_ $$aFrontzkowski, Lukas$$b6
000283095 7001_ $$aHirsch, Fabian$$b7
000283095 7001_ $$0P:(DE-2719)9001539$$aBrendel, Matthias$$b8$$udzne
000283095 7001_ $$aFranzmeier, Nicolai$$b9
000283095 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz70862_110180$$gVol. 21 Suppl 8, no. Suppl 8, p. e110180$$nSuppl 8$$pe110180$$tAlzheimer's and dementia$$v21$$x1552-5260$$y2025
000283095 8564_ $$uhttps://pub.dzne.de/record/283095/files/DZNE-2025-1502.pdf$$yOpenAccess
000283095 8564_ $$uhttps://pub.dzne.de/record/283095/files/DZNE-2025-1502.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000283095 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001539$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000283095 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000283095 9141_ $$y2025
000283095 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
000283095 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
000283095 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000283095 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283095 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-01-06$$wger
000283095 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-06
000283095 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283095 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-06
000283095 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000283095 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-06
000283095 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-06
000283095 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-06
000283095 9201_ $$0I:(DE-2719)1110007$$kAG Haass$$lMolecular Neurodegeneration$$x0
000283095 980__ $$aabstract
000283095 980__ $$aVDB
000283095 980__ $$aUNRESTRICTED
000283095 980__ $$ajournal
000283095 980__ $$aI:(DE-2719)1110007
000283095 9801_ $$aFullTexts